Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 1
1948 2
1949 2
1951 1
1952 5
1953 4
1954 3
1955 5
1956 4
1957 4
1958 5
1959 3
1960 1
1961 5
1963 2
1964 2
1965 2
1966 2
1967 1
1968 5
1970 3
1972 1
1974 2
1975 1
1976 2
1978 3
1979 3
1980 4
1981 4
1982 3
1983 1
1984 4
1985 2
1986 4
1987 5
1988 3
1989 5
1990 8
1991 2
1992 2
1993 3
1994 7
1995 2
1996 6
1997 8
1998 5
1999 6
2000 6
2001 5
2002 8
2003 11
2004 5
2005 9
2006 18
2007 13
2008 15
2009 13
2010 17
2011 19
2012 19
2013 21
2014 21
2015 38
2016 30
2017 24
2018 31
2019 19
2020 26
2021 28
2022 36
2023 29
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

575 results

Results by year

Filters applied: . Clear all
Proximity search should include two or more words. Proximity operator ignored :~0
Page 1
Primary myelofibrosis: 2023 update on diagnosis, risk-stratification, and management.
Tefferi A. Tefferi A. Am J Hematol. 2023 May;98(5):801-821. doi: 10.1002/ajh.26857. Epub 2023 Feb 6. Am J Hematol. 2023. PMID: 36680511 Free article. Review.
NEW CLASSIFICATION SYSTEM: The International Consensus Classification distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former might mimic essential thrombocythemia (ET) in its presentation. Approximately 15% of patients with ET or polycythemia vera (PV) might p …
NEW CLASSIFICATION SYSTEM: The International Consensus Classification distinguishes "prefibrotic" from "overtly fibrotic" PMF; the former mi …
Polycythemia vera: 2024 update on diagnosis, risk-stratification, and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2023 Sep;98(9):1465-1487. doi: 10.1002/ajh.27002. Epub 2023 Jun 26. Am J Hematol. 2023. PMID: 37357958 Review.
Cytoreductive therapy is reserved for high-risk disease with first-line drugs of choice being hydroxyurea and pegylated interferon-alpha and second-line busulfan and ruxolitinib. ...The current review also includes specific treatment strategies in the context of pregnancy, …
Cytoreductive therapy is reserved for high-risk disease with first-line drugs of choice being hydroxyurea and pegylated interferon-al …
Primary myelofibrosis: 2021 update on diagnosis, risk-stratification and management.
Tefferi A. Tefferi A. Am J Hematol. 2021 Jan;96(1):145-162. doi: 10.1002/ajh.26050. Epub 2020 Dec 2. Am J Hematol. 2021. PMID: 33197049 Free article. Review.
Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutations are also prevalent in the closely related MPNs, namely polycythemia vera (PV) and essential thrombocythemia (ET). The 2016 World …
Presence of JAK2, CALR, or MPL mutation, expected in around 90% of the patients, is supportive but not essential for diagnosis; these mutati …
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk-stratification and management.
Tefferi A, Barbui T. Tefferi A, et al. Am J Hematol. 2020 Dec;95(12):1599-1613. doi: 10.1002/ajh.26008. Epub 2020 Oct 23. Am J Hematol. 2020. PMID: 32974939 Free article. Review.
All patients with PV require phlebotomy to keep hematocrit below 45% and once-daily or twice-daily aspirin (81 mg), in the absence of contraindications. Very low risk ET might not require therapy while aspirin therapy is advised for low risk disease. Cytoreductive …
All patients with PV require phlebotomy to keep hematocrit below 45% and once-daily or twice-daily aspirin (81 mg), in the absence of contra …
Essential thrombocythemia: 2024 update on diagnosis, risk stratification, and management.
Tefferi A, Vannucchi AM, Barbui T. Tefferi A, et al. Am J Hematol. 2024 Apr;99(4):697-718. doi: 10.1002/ajh.27216. Epub 2024 Jan 25. Am J Hematol. 2024. PMID: 38269572 Review.
Cytoreductive therapy is advised for high-risk and optional for intermediate-risk disease. ...ADDITIONAL CONTENT: The current review includes specific treatment strategies in the context of extreme thrombocytosis, pregnancy, splanchnic vein thrombosis, perioperative car …
Cytoreductive therapy is advised for high-risk and optional for intermediate-risk disease. ...ADDITIONAL CONTENT: The current review …
Thrombocytosis in children and adolescents-classification, diagnostic approach, and clinical management.
Stockklausner C, Duffert CM, Cario H, Knöfler R, Streif W, Kulozik AE; THROMKID-Plus Studiengruppe der Gesellschaft für Thrombose- und Hämostaseforschung (GTH) and of Gesellschaft für Pädiatrische Onkologie und Hämatologie (GPOH). Stockklausner C, et al. Ann Hematol. 2021 Jul;100(7):1647-1665. doi: 10.1007/s00277-021-04485-0. Epub 2021 Mar 12. Ann Hematol. 2021. PMID: 33712866 Free PMC article. Review.
Furthermore, somatic mutations in JAK2, MPL, and in the gene-encoding calreticulin (CALR) have been described to act as driver mutations within the so-called Philadelphia-negative myeloproliferative neoplasms (MPNs), namely essential thrombocythemia (ET), polycythemia vera …
Furthermore, somatic mutations in JAK2, MPL, and in the gene-encoding calreticulin (CALR) have been described to act as driver mutations wit …
Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Barbui T, Tefferi A, Vannucchi AM, Passamonti F, Silver RT, Hoffman R, Verstovsek S, Mesa R, Kiladjian JJ, Hehlmann R, Reiter A, Cervantes F, Harrison C, Mc Mullin MF, Hasselbalch HC, Koschmieder S, Marchetti M, Bacigalupo A, Finazzi G, Kroeger N, Griesshammer M, Birgegard G, Barosi G. Barbui T, et al. Leukemia. 2018 May;32(5):1057-1069. doi: 10.1038/s41375-018-0077-1. Epub 2018 Feb 27. Leukemia. 2018. PMID: 29515238 Free PMC article. Review.
Key differences from the 2011 diagnostic recommendations included: lower threshold values for hemoglobin and hematocrit and bone marrow examination for diagnosis of polycythemia vera (PV), according to the revised WHO criteria; the search for complementary clonal markers, …
Key differences from the 2011 diagnostic recommendations included: lower threshold values for hemoglobin and hematocrit and bone marrow exam …
Current management strategies for polycythemia vera and essential thrombocythemia.
Guglielmelli P, Vannucchi AM. Guglielmelli P, et al. Blood Rev. 2020 Jul;42:100714. doi: 10.1016/j.blre.2020.100714. Epub 2020 Jun 3. Blood Rev. 2020. PMID: 32546373 Review.
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiovascular events, a varying burden of symptoms, and an intrinsic risk of evolution to secondary forms of myelofibrosis and acute leukemia; how …
Polycythemia vera (PV) and essential thrombocythemia (ET) are myeloproliferative neoplasms characterized by increased rate of cardiov …
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management.
Gangat N, Szuber N, Tefferi A. Gangat N, et al. Am J Hematol. 2023 Jun;98(6):965-981. doi: 10.1002/ajh.26920. Epub 2023 Apr 3. Am J Hematol. 2023. PMID: 36966432 Free article.
DISEASE OVERVIEW: JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses a heterogenous spectrum of hereditary and acquired entities. ...Prospective controlled studies are needed to clarify potential pathology from JAK2 unmutated erythrocytosis, as well as …
DISEASE OVERVIEW: JAK2 unmutated or non-polycythemia vera (PV) erythrocytosis encompasses a heterogenous spectrum of hereditary and a …
Pathophysiology, diagnosis, and management of twin anemia polycythemia sequence in monochorionic multiple gestations.
Baschat AA, Miller JL. Baschat AA, et al. Best Pract Res Clin Obstet Gynaecol. 2022 Nov;84:115-126. doi: 10.1016/j.bpobgyn.2022.03.012. Epub 2022 Mar 30. Best Pract Res Clin Obstet Gynaecol. 2022. PMID: 35450772 Review.
Twin anemia polycythemia sequence (TAPS) is a consequence of unequal sharing of red blood cells between monochorionic twins resulting in anemia in the donor and polycythemia in the recipient twin. ...
Twin anemia polycythemia sequence (TAPS) is a consequence of unequal sharing of red blood cells between monochorionic twins resulting …
575 results